Endoscopic Gastric Sleeve vs Gastric Sleeve Surgery

Both endoscopic sleeve gastroplasty and gastric sleeve surgery (VSG or vertical sleeve gastrectomy) reduce stomach volume but the similarity largely ends there. One is an endoscopic procedure performed through the mouth with no incisions; the other is a laparoscopic bariatric operation that permanently removes the majority of the stomach. 

The clinical outcomes they produce, the metabolic mechanisms they engage, and the patient profiles they serve are meaningfully different. For patients comparing the two, understanding those differences is more useful than focusing on the shared word “sleeve.”

Endoscopic gastric sleeve (ESG) is performed through the mouth using a flexible endoscope. While in the gastric sleeve, a laparoscopic method is used. In ESG, there are no external incisions made, in gastric sleeve, 4-5 incisions are made on the belly. In ESG, a suturing device is used endoscopically whereas in sleeve, it is used laparoscopically. In ESG, the stomach is sutured internally, in gastric sleeve approximately 80% of the stomach is removed and then stapled.

The core distinction is that the endoscopic gastric sleeve is an endoscopic restriction; gastric sleeve is metabolic bariatric surgery. These are not equivalent approaches to the same outcome.

ESG works by reducing the internal volume of the stomach through sutures that cinch the greater curvature inward. Food intake is limited by the smaller space, and gastric emptying slows, which extends the feeling of fullness after meals. Surgical sleeve gastrectomy achieves restriction through permanent stomach removal, but its effect on weight regulation extends well beyond the mechanical limitation of a smaller stomach.

In ESG, the stomach itself is not altered anatomically, the tissue remains in place, the intestinal pathway is unchanged, and no hormonal mechanism is engaged by the procedure. Weight loss depends on the restriction holding and on sustained behavioral change by the patient. In VSG, removing the fundus eliminates the primary site of ghrelin production, producing a sustained reduction in baseline hunger that does not depend on patient discipline. The altered gastric anatomy also stimulates increased secretion of GLP-1 and other satiety hormones, improving insulin sensitivity and supporting long-term weight regulation through hormonal pathways. These metabolic changes occur independently of food intake and continue to influence weight and metabolic health over the years following surgery. This hormonal dimension is why sleeve gastrectomy produces more consistent and durable outcomes than restriction alone.

This distinction matters most for patients with obesity-related metabolic disease and it is where the two procedures diverge most significantly.

Gastric sleeve surgery drives a set of hormonal changes that begin in the early postoperative period and persist long-term. Ghrelin production falls substantially after the fundus is removed, reducing the hormonal drive to eat between meals. GLP-1 secretion increases, which improves insulin sensitivity, supports glycemic regulation, and contributes to satiety signaling after meals. These effects are why sleeve gastrectomy consistently improves or resolves type 2 diabetes, even before significant weight loss has occurred. The procedure is classified as metabolic bariatric surgery precisely because its benefits extend beyond caloric restriction.

ESG does not engage these pathways. Because the fundus is folded rather than removed, ghrelin suppression does not occur at a clinically meaningful level. GLP-1 changes following ESG are minimal. The procedure produces no significant improvement in insulin sensitivity through hormonal mechanisms. Any glycemic benefit observed after ESG is secondary to weight loss itself, not to a direct metabolic effect of the intervention.

For patients whose primary concern is weight reduction alone, this distinction is relevant. For patients with type 2 diabetes, metabolic syndrome, or significant cardiovascular risk, it is decisive.

The weight loss gap between the two procedures is substantial and consistent across published studies.

Procedure	Average Weight Loss	Mechanism	Durability
Endoscopic Gastric Sleeve	15–20% total body weight	Restriction	Variable
Gastric Sleeve Surgery	25–30% total body weight	Restriction + Hormonal	Long-term

ESG outcomes vary considerably depending on dietary adherence, the integrity of the sutures over time, and whether patients receive structured follow-up support. Some patients achieve results at the higher end of the reported range; many do not sustain them beyond two to three years as sutures loosen and restriction diminishes.

Surgical sleeve gastrectomy produces more consistent and durable weight loss across patient populations because its mechanism does not depend on suture integrity or behavioral compliance alone. The hormonal changes driven by stomach removal continue to support weight regulation long after the operation.

Both procedures carry risks, and understanding the complication profile of each helps patients make an informed comparison rather than assuming that an endoscopic procedure is automatically safer.

Complication Type	Endoscopic Gastric Sleeve (ESG)	Gastric Sleeve Surgery
Bleeding	Can occur during suture placement inside the stomach wall	May occur along the surgical staple line
Perforation	Possible during endoscopic manipulation of the stomach wall	Rare but possible if surgical complications occur
Device / Structural Failure	Sutures may loosen over time, reducing restriction	Staple line complications such as leaks may occur
Gastrointestinal Symptoms	Nausea and abdominal discomfort are common early after the procedure	Post-operative nausea and temporary intolerance may occur
Reflux	Less commonly reported	Reflux symptoms may worsen in some patients

While both procedures have recognized risks, surgical sleeve gastrectomy has been studied for more than two decades, providing extensive data on complication rates and long-term outcomes. Endoscopic sleeve gastroplasty, by comparison, has a shorter clinical history and more limited long-term data.

Experienced bariatric surgeons evaluate procedures by their long-term metabolic outcomes, durability of weight loss, and impact on obesity-related disease. By these criteria, surgical sleeve gastrectomy remains one of the most widely performed bariatric procedures in the world and the standard against which newer options are measured.

ESG is not viewed by most high-volume bariatric programs as a primary metabolic surgery. It occupies a specific niche: patients who prefer to avoid surgery, fall in a lower BMI range, or are not candidates for general anesthesia. Outside of that patient profile, the evidence base supporting sleeve gastrectomy is substantially stronger in terms of weight loss magnitude, hormonal effect, and long-term follow-up data.

This preference reflects clinical evidence rather than institutional bias. Surgeons who perform both procedures apply the same standard. It is decided on which intervention is most likely to produce durable improvement in this specific patient’s health over five, ten, and fifteen years.

The right procedure depends on individual health status, BMI, metabolic diseass, and a realistic assessment of what each intervention can deliver.

ESG may be appropriate for patients with a BMI in the 30–40 range who prefer a non-surgical approach, are not ready for bariatric surgery, or have medical contraindications to general anesthesia. It works best when combined with structured dietary support and behavioral follow-up.

Gastric sleeve surgery is generally recommended for patients with moderate to severe obesity, obesity-related metabolic disease, or those seeking more durable and hormonally driven weight loss. It is also the more appropriate choice for patients whose long-term goal includes disease remission, not just weight reduction.

No procedure should be selected based on convenience alone. A formal medical evaluation with a bariatric specialist is the appropriate starting point for any patient weighing these options.